Introducing Martini Market: A Decentralized Prediction Market on the XRP Ledger
By GlobeNewswire Published on May 28, 2025, 02:50 IST
DUBAI, United Arab Emirates, May 27, 2025 (GLOBE NEWSWIRE) — As the XRP Ledger (XRPL) continues its evolution into a robust platform for decentralized finance (DeFi), the emergence of innovative applications is reshaping the landscape.
Among these, Martini Market stands out as the first decentralized prediction market built natively on XRPL, offering users a platform to speculate on real-world events with speed, security, and transparency.
Why Martini Market Matters
Martini Market introduces a novel approach to prediction markets by leveraging the inherent advantages of XRPL: Rapid Settlement: Transactions settle in seconds, ensuring timely execution of bets and payouts.
Transactions settle in seconds, ensuring timely execution of bets and payouts. Low Fees: XRPL's efficient design translates to minimal transaction costs, making micro-betting feasible.
XRPL's efficient design translates to minimal transaction costs, making micro-betting feasible. Decentralization: Built on a public blockchain, Martini Market operates without intermediaries, enhancing trust and accessibility.
These features position Martini Market to serve a global audience interested in forecasting outcomes across various domains from politics and sports to cryptocurrency price movements.
The $MRT Token: Powering the Ecosystem
Central to Martini Market's functionality is the $MRT token , which serves multiple roles within the platform: Market Creation: Users stake $MRT to propose new prediction markets, ensuring commitment and reducing spam.
Users stake $MRT to propose new prediction markets, ensuring commitment and reducing spam. Governance: Token holders participate in decision-making processes, influencing platform developments and policies.
Token holders participate in decision-making processes, influencing platform developments and policies. Staking Rewards: By staking $MRT, users can earn a share of platform fees, aligning incentives with the platform's growth.
This multifaceted utility fosters an engaged community and promotes the sustainable development of the Martini Market ecosystem.
Aligning with XRPL's DeFi Trajectory
Martini Market's launch coincides with XRPL's strategic push into institutional DeFi.
Recent developments include the introduction of automated market makers (AMMs) and the anticipated deployment of an Ethereum Virtual Machine (EVM) sidechain, enhancing XRPL's programmability and attracting a broader range of decentralized applications.
These advancements create a fertile environment for platforms like Martini Market to thrive, offering users innovative financial tools within a secure and scalable infrastructure.
Explore Martini Market
To learn more about Martini Market and participate in the evolving world of decentralized prediction markets, visit our official channels below.
Join us as we build the polyMarket of the XRP Ecosystem.
Contact:Picard Beaumont
[email protected]
Disclaimer: This is a paid post and is provided by Martini Market. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice.Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be guaranteed.
Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. GlobeNewswire does not endorse any content on this page.
Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4164ef27-21a7-4498-853c-2fb2766a2ca7
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
BitMEX Study Reveals 90% Drop in Extreme Bitcoin Perpetual Futures Funding Rates Since 2016, Signalling Market Maturation
Mahe, Seychelles, June 30th, 2025, Chainwire BitMEX, the safest crypto exchange, today announced the findings of its comprehensive study on XBTUSD, the longest-running Bitcoin perpetual swap, to shed light on the evolution of the funding rate market. The research, spanning from May 2016 to May 2025, reveals a significant shift in funding rate patterns, marking a transition from high volatility to unprecedented market stability. Since BitMEX pioneered perpetual swaps in 2016, they've become one of the most traded financial products worldwide. A key component of these products are funding rates, which are periodic payments made between long and short position holders of a perpetual swap contract to maintain a token's futures price with its spot price. Funding rates are crucial for identifying market arbitrage opportunities and to gauge market sentiment. The study, which delved into the extensive history of BitMEX's XBTUSD perpetual swap, uncovered several key insights: Extreme Funding Rates Plummet by 90%: Since 2016, the occurrence of extreme funding rates has dropped by a staggering 90%. Notably, data from 2024-2025 shows remarkable stability, even as Bitcoin surged past $100,000. This trend indicates a clear maturation of the crypto market, transforming Bitcoin from a highly speculative asset into a more stable financial instrument. Mainstream Integration Drives Stability: The launch of Bitcoin ETFs in January 2024 and the emergence of decentralised finance (DeFi) protocols like Ethena have been instrumental in facilitating large-scale arbitrage, further anchoring futures prices to spot prices and contributing to market efficiency. Era of Stable Funding Rates: The current environment of stable funding rates suggests significantly reduced market volatility. This stability could position Bitcoin as a more reliable asset for institutional portfolios, with potential wider implications for traditional financial markets. "Our study highlights a profound transformation in the Bitcoin perpetual swap market," said Stephan Lutz, CEO of BitMEX. "The dramatic reduction in extreme funding rates on XBTUSD underscores the growing maturity and institutional acceptance of crypto. As one of the oldest crypto exchanges, we're excited to be able to share such market insights for our traders and reinforce the industry's integration into the global financial landscape.' More details about the study can be found here. About BitMEX BitMEX is the OG crypto derivatives exchange, providing professional crypto traders with a platform that caters to their needs through low latency, deep crypto native liquidity and unmatched reliability. Since its founding, no cryptocurrency has been lost through intrusion or hacking, allowing BitMEX users to trade safely in the knowledge that their funds are secure. So too that they have access to the products and tools they require to be profitable. BitMEX was also one of the first exchanges to publish their on-chain Proof of Reserves and Proof of Liabilities data. The exchange continues to publish this data twice a week – proving assurance that they safely store and segregate the funds they are entrusted with. For more information on BitMEX, users can visit the BitMEX Blog or and follow Telegram, Twitter, Discord, and its online communities. For further inquiries, users can contact press@
Associated Press
an hour ago
- Associated Press
Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market SOLANA BEACH, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced favorable results from its first-in-human study evaluating ART26.12, a novel inhibitor of Fatty Acid Binding Protein 5 (FABP5). The results affirm the promising safety and pharmacokinetic (PK) profile previously observed in preclinical studies. Inhibiting FABP5 represents a unique mechanism of action with ART26.12 standing out as a first-in-class candidate in the field of pain management. The Phase 1 Single Ascending Dose (SAD) study was designed to assess the safety, tolerability, and pharmacokinetics of ART26.12 in healthy volunteers. The SAD study enrolled 49 subjects. The key findings include: Andrew Yates, Ph.D., Senior Vice President and Chief Scientific Officer at Artelo, commented, 'We are greatly encouraged with the results of the SAD study with our lead FABP5 inhibitor and we are particularly pleased to observe that the safety and PK profile that had been generated from ART26.12's non-clinical studies translated well to the human experience.' ART26.12 is the first orally administered, selective, and peripherally restricted FABP5 inhibitor to enter human clinical evaluation. By targeting FABP5, ART26.12 modulates endogenous lipid signaling molecules that exert analgesic effects through established pathways, including TRPV1, PPAR alpha, and cannabinoid receptors, with additional mechanisms such as Nav1.8 under investigation. The chronic pain therapeutics market exceeded $97 billion globally in 2023 and is expected to surpass $159 billion by 20301, driven by the increasing prevalence of conditions such as neuropathic pain, arthritis, and fibromyalgia. Despite the scale of the market, innovation remains sparse—particularly for non-opioid therapies. As part of the U.S Food and Drug Administration's Overdose Prevention Framework, the Agency has issued draft guidance aimed at encouraging the development of non-opioid analgesics for pain. ART26.12 is positioned to fill this gap with an innovative mechanism of action and favorable safety profile. A Multiple Ascending Dose study to further evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year. About ART26.12 ART26.12, Artelo's lead FABP5 inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). FABPs are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in several pathologies. In addition to ART26.12 in CIPN, Artelo's extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, anxiety disorders, and psoriasis. ART26.12 has been included in Helping to End Addiction Long-term® (HEAL) Initiative's Preclinical Screening Platform for Pain program of the U.S. National Institutes of Health. The HEAL program is dedicated to advancing non-opioid solutions to pain and curbing opioid use disorder. 1 About Artelo Biosciences Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at and X: @ArteloBio. Forward-Looking StatementsInvestor Relations Contact: Crescendo Communications, LLC Tel: 212-671-1020 Email: [email protected]
Yahoo
an hour ago
- Yahoo
Wearable and Non-Invasive Technologies Set to Revolutionize the $37.5 Bn Market
The Global Diabetes Testing System Market, valued at USD 21.48 Billion in 2025, is projected to reach USD 33.19 Billion by 2034, growing at a CAGR of 6.4%. With rising diabetes prevalence, demand for innovative and user-friendly diagnostic solutions, like CGMs and AI-driven systems, is surging. North America dominates the market, while Asia-Pacific sees rapid expansion. Key trends include wearable technology, minimally invasive methods, and digital health integration, enhancing diabetes management. Diabetes Testing System Market Dublin, June 30, 2025 (GLOBE NEWSWIRE) -- The "Diabetes Testing System Market Size, Share, Trends, Analysis, and Forecast 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges" has been added to Global Diabetes Testing System Market is poised for significant growth, with its size valued at USD 21.48 billion in 2025. Anticipated to expand at a CAGR of 6.4%, the market is projected to reach USD 33.19 billion by 2034. Key factors propelling this growth include aging populations, sedentary lifestyles, rising obesity rates, and increased incidence of both Type 1 and Type 2 diabetes. Diabetes testing systems, crucial to the healthcare ecosystem, encompass blood glucose meters, continuous glucose monitoring (CGM) devices, test strips, lancets, and advanced digital platforms. These tools collectively facilitate effective diabetes management by delivering real-time, user-friendly testing solutions. Technological advancements in wearable devices, minimally invasive sampling, and digital health integration are reshaping diabetes management across healthcare settings. Notably, North America leads the market, bolstered by robust healthcare infrastructure, favorable reimbursement policies, and high disease management awareness. Meanwhile, Asia-Pacific experiences rapid growth due to improving healthcare access and urbanization, alongside burgeoning diabetes cases. The competitive landscape is marked by innovation and strategic initiatives, with companies launching connected devices offering real-time monitoring, mobile app integration, and remote physician access. A focus on non-invasive technology, AI-driven insights, and compact systems for personalized care defines current market dynamics. Future success hinges on regulatory trends, affordability, and patient-centric design innovations. Key Takeaways - Diabetes Testing System Market: Rising diabetes prevalence drives demand for accurate and accessible self-monitoring and clinical testing systems. Blood glucose meters and CGMs dominate the technology landscape in diabetes testing. Next-gen CGMs equipped with real-time data, Bluetooth connectivity, and smartphone integration enhance glucose tracking. Minimally invasive and needle-free systems are emerging to boost patient compliance and convenience. AI-driven analytics and personalized alerts enhance proactive glucose management and complication prevention. Cloud-based platforms promote data sharing between patients, caregivers, and clinicians for remote diabetes management. Challenges entail pricing pressure, regulatory approvals, and the demand for improved accuracy and calibration-free solutions. Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $21.48 Billion Forecasted Market Value (USD) by 2034 $37.54 Billion Compound Annual Growth Rate 6.4% Regions Covered Global Market Segmentation: By Product: Blood Glucose Monitors, Continuous Glucose Monitoring Systems, Test Strips. By Application: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes. By End User: Hospitals, Home Care, Diagnostic Centers. By Technology: Self-Monitoring, Continuous Monitoring, Smart Device Integration. By Distribution Channel: Online Retail, Pharmacies, Hospital Distributors. By Geography: North America, Europe, Asia-Pacific, Middle East and Africa, South and Central America. Companies Featured Abbott Laboratories Roche Diabetes Care Dexcom, Inc. Medtronic plc Becton, Dickinson and Company Ascensia Diabetes Care LifeScan, Inc. Senseonics Holdings, Inc. ARKRAY, Inc. Nova Biomedical Corporation Ypsomed Holding AG GlucoMe Ltd. Nipro Corporation Terumo Corporation AgaMatrix, Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Diabetes Testing System Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
